Anacor Stayed Positive among the Hammered Mid-Caps



Hammered mid-caps

It was a tough week for the mid-cap space of the biotech ETFs. Mid-caps fell for the week ending December 11, 2015. The iShares US Medical Devices ETF’s (IHI) mid-caps were the best. They fell by 2.2%. The SPDR S&P Biotech ETF’s (XBI) mid-caps fell badly. They had a return of -6.2%. Among the 18 mid-cap stocks held by IHI, Abiomed (ABMD) was the only mid-cap stock with positive returns. Stocks like Bluebird Bio (BLUE), Acadia Pharmaceuticals (ACAD), and Agios Pharmaceuticals (AGIO) dragged XBI’s mid-caps. They had returns of -28.85%, -10,1%, and -13.15%, respectively.

The above graph shows the performances of mid-cap biotech stocks compared to the SPDR S&P 500 ETF (SPY) on a week-over-week basis.

Article continues below advertisement

Anacor remained positive for the week

Anacor Pharmaceuticals (ANAC) was one of the top mid-cap performers for the week. It rose by 5.9% for the week. The stock rose due to good trading volumes. So far, it had gains for four consecutive trading sessions. Anacor’s average trading volume for the week was ~592,000 shares per day. It closed at $117.21 for the week. It was trading below the 100-day moving average price of $123. However, it was trading above the 20-day moving average price of $112.22.

Anacor has an RSI (Relative Strength Index) of 56. This indicates that the stock isn’t overbought or oversold. YTD (year-to-date), Anacor had a return of 263%. It has a book value of $1.38 per share. With its current price, the stock is trading at a PBV (price-to-book value) ratio of 85.17x. Anacor has a weight of ~0.85% in the SPDR S&P Biotech ETF’s (XBI) portfolio. It has a weight of 0.75% in the iShares Nasdaq Biotechnology ETF (IBB).


More From Market Realist